Factors Associated with Delirium in COVID-19 Patients and Their Outcome: A Single-Center Cohort Study.
C-reactive protein
COVID-19
delirium
mortality
neutrophils-to lymphocyte ratio
Journal
Diagnostics (Basel, Switzerland)
ISSN: 2075-4418
Titre abrégé: Diagnostics (Basel)
Pays: Switzerland
ID NLM: 101658402
Informations de publication
Date de publication:
20 Feb 2022
20 Feb 2022
Historique:
received:
25
01
2022
revised:
10
02
2022
accepted:
16
02
2022
entrez:
25
2
2022
pubmed:
26
2
2022
medline:
26
2
2022
Statut:
epublish
Résumé
A significant proportion of patients with coronavirus disease 2019 (COVID-19) suffer from delirium during hospitalization. This single-center observational study investigates the occurrence of delirium, the associated risk factors and its impact on in-hospital mortality in an Italian cohort of COVID 19 inpatients. Data were collected in the COVID units of a general medical hospital in the South of Italy. Socio-demographic, clinical and pharmacological features were collected. Diagnosis of delirium was based on a two-step approach according to 4AT criteria and DSM5 criteria. Outcomes were: dates of hospital discharge, Intensive Care Unit (ICU) admission, or death, whichever came first. Univariable and multivariable proportional hazards Cox regression models were estimated, and risks were reported as hazard ratios (HR) along with their 95% confidence intervals (95% CI). A total of 47/214 patients (22%) were diagnosed with delirium (21 hypoactive, 15 hyperactive, and 11 mixed). In the multivariable model, four independent variables were independently associated with the presence of delirium: dementia, followed by age at admission, C-reactive protein (CRP), and Glasgow Coma Scale. In turn, delirium was the strongest independent predictor of death/admission to ICU (composite outcome), followed by Charlson Index (not including dementia), CRP, and neutrophil-to-lymphocyte ratio. The probability of reaching the composite outcome was higher for patients with the hypoactive subtype than for those with the hyperactive subtype. Delirium was the strongest predictor of poor outcome in COVID-19 patients, especially in the hypoactive subtype. Several clinical features and inflammatory markers were associated with the increased risk of its occurrence. The early recognition of these factors may help clinicians to select patients who would benefit from both non-pharmacological and pharmacological interventions in order to prevent delirium, and in turn, reduce the risk of admission to ICU or death.
Sections du résumé
BACKGROUND
BACKGROUND
A significant proportion of patients with coronavirus disease 2019 (COVID-19) suffer from delirium during hospitalization. This single-center observational study investigates the occurrence of delirium, the associated risk factors and its impact on in-hospital mortality in an Italian cohort of COVID 19 inpatients.
METHODS
METHODS
Data were collected in the COVID units of a general medical hospital in the South of Italy. Socio-demographic, clinical and pharmacological features were collected. Diagnosis of delirium was based on a two-step approach according to 4AT criteria and DSM5 criteria. Outcomes were: dates of hospital discharge, Intensive Care Unit (ICU) admission, or death, whichever came first. Univariable and multivariable proportional hazards Cox regression models were estimated, and risks were reported as hazard ratios (HR) along with their 95% confidence intervals (95% CI).
RESULTS
RESULTS
A total of 47/214 patients (22%) were diagnosed with delirium (21 hypoactive, 15 hyperactive, and 11 mixed). In the multivariable model, four independent variables were independently associated with the presence of delirium: dementia, followed by age at admission, C-reactive protein (CRP), and Glasgow Coma Scale. In turn, delirium was the strongest independent predictor of death/admission to ICU (composite outcome), followed by Charlson Index (not including dementia), CRP, and neutrophil-to-lymphocyte ratio. The probability of reaching the composite outcome was higher for patients with the hypoactive subtype than for those with the hyperactive subtype.
CONCLUSIONS
CONCLUSIONS
Delirium was the strongest predictor of poor outcome in COVID-19 patients, especially in the hypoactive subtype. Several clinical features and inflammatory markers were associated with the increased risk of its occurrence. The early recognition of these factors may help clinicians to select patients who would benefit from both non-pharmacological and pharmacological interventions in order to prevent delirium, and in turn, reduce the risk of admission to ICU or death.
Identifiants
pubmed: 35204633
pii: diagnostics12020544
doi: 10.3390/diagnostics12020544
pmc: PMC8871116
pii:
doi:
Types de publication
Journal Article
Langues
eng
Références
Age Ageing. 2007 Mar;36(2):222-5
pubmed: 17114198
J Neurol Neurosurg Psychiatry. 2021 Feb;92(2):218-220
pubmed: 33055146
BMJ Open. 2021 Dec 13;11(12):e048323
pubmed: 34903533
Neurology. 2020 Aug 18;95(7):e910-e920
pubmed: 32444493
Aging Ment Health. 2021 Oct 15;:1-8
pubmed: 34651536
J Am Geriatr Soc. 2017 Aug;65(8):e109-e116
pubmed: 28555781
JAMA Netw Open. 2020 Nov 2;3(11):e2029540
pubmed: 33211114
Front Cell Neurosci. 2020 Nov 11;14:592214
pubmed: 33304243
Diagnostics (Basel). 2021 Feb 25;11(3):
pubmed: 33668734
Neurol Sci. 2021 Apr;42(4):1527-1530
pubmed: 33185785
Age Ageing. 2014 Jul;43(4):496-502
pubmed: 24590568
BMJ. 2020 May 22;369:m1985
pubmed: 32444460
J Clin Epidemiol. 1994 Nov;47(11):1245-51
pubmed: 7722560
Ann Palliat Med. 2021 May;10(5):5069-5083
pubmed: 33894729
J Neurosci. 2020 Jul 15;40(29):5681-5696
pubmed: 32513828
Age Ageing. 2021 Sep 11;50(5):1445-1453
pubmed: 33984129
Age Ageing. 2020 Jul 1;49(4):497-498
pubmed: 32374367
Lancet Respir Med. 2021 Mar;9(3):239-250
pubmed: 33428871
JAMA Psychiatry. 2021 Jun 1;78(6):682-683
pubmed: 33769431
Immunity. 2020 Jun 16;52(6):910-941
pubmed: 32505227
J Med Virol. 2020 Nov;92(11):2409-2411
pubmed: 32516845
Am J Emerg Med. 2021 Apr;42:60-69
pubmed: 33453617
Intensive Care Med. 2020 May;46(5):1020-1022
pubmed: 32055887
Nat Rev Dis Primers. 2020 Nov 12;6(1):90
pubmed: 33184265
Nature. 2020 Aug;584(7821):430-436
pubmed: 32640463
Lancet Psychiatry. 2020 Jul;7(7):611-627
pubmed: 32437679
J Psychosom Res. 2021 Feb;141:110350
pubmed: 33401078
Arch Gerontol Geriatr. 2021 Jul-Aug;95:104388
pubmed: 33713880
Crit Care Med. 2020 Mar;48(3):353-361
pubmed: 31770149
Biol Psychiatry. 2017 Jan 15;81(2):145-153
pubmed: 27160518